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Abstract
Objectives: to investigate the immunoexpression of epidermal growth factor receptor (EGFR) in a sample of oral 
leukoplakias (OL) and to determine the receptor’s association with dysplasia, tobacco consumption, lesion site, 
and proliferation rate. Although EGFR should be overexpressed in some oral leukoplakias, the factors that may 
interfere with this expression and the influence of this receptor on epithelial proliferation have yet to be investi-
gated.
Study Design: Samples of oral leukoplakias (48) and of normal oral epithelium (10) were immunohistologically 
examined for expression of EGFR. Immunohistochemistry for Ki-67, and p27 were also performed in leukopla-
kias. EGFR expression was associated with clinical and pathological features. 
Results: EGFR was positive in 62.5% of the leukoplakias and 50% of normal oral epithelium. The number of 
EGFR positive OL located in high-risk sites was significantly higher than EGFR positive OL located in low-risk 
sites. Most of the p27 negative leukoplakias were EGFR positive, and the p27 index in the parabasal layer was 
diminished in the presence of dysplasia. Positivity for EGFR was not associated with dysplasia, tobacco exposure, 
or Ki-67.
Conclusion: EGFR is expressed in leukoplakia regardless of dysplasia, but EGFR positivity should be more fre-
quent in lesions sited in areas of high cancer risk. The association between EGFR and p27 may represent an impor-
tant mechanism in the control of cellular proliferation and malignant progression of oral epithelium and therefore 
warrants further investigation.
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Introduction
Leukoplakia is a potentially malignant disorder of the 
oral mucosa that is defined as a white patch or plaque of 
questionable risk that cannot be characterized clinically 
or pathologically as any other known disease (1) Upon 
biopsy, some leukoplakias may exhibit epithelial dys-
plasia that is likely associated with progression to can-
cer (2,3). Other features of leukoplakias, such as smo-
king (4,5) and location on the floor of the mouth and/or 
on the tongue (2,6), have also been associated with an 
increased risk of malignant transformation.
Several studies have attempted to identify biomarkers 
that may be useful in predicting malignant transforma-
tion (7). The epidermal growth factor receptor (EGFR) 
is a member of a family of tyrosine kinase receptors that 
are overexpressed in several types of cancers, including 
the oral squamous cell carcinoma (OSCC) (8-10). There 
is substantial evidence that high expression of EGFR is 
correlated with advanced tumor stages, metastases, and 
poor clinical outcomes (11). Previous studies have also 
indicated that EGFR upregulation may be a useful mar-
ker for identifying individuals at risk of OSCC deve-
lopment (12-15) However, clinicopathological features 
of lesions that may interfere with EGFR expression in 
potentially malignant disorders have yet to be investi-
gated.
The exact mechanisms involved in the control of cellu-
lar proliferation through the EGFR pathway are not fu-
lly understood. Recently, preclinical studies examining 
EGFR have shown that tyrosine kinase inhibitors block 
EGFR tyrosine kinase activity, resulting in inhibition 
of cell proliferation and upregulation of p27 in OSCC 
cells (16-18).
The expression of EGFR in leukoplakias is likely alte-
red by clinicopathological features and may modulate 
proliferation indexes. The present study evaluated the 
immunoexpression of EGFR in a sample of oral leuko-
plakia and its association with dysplasia, tobacco con-
sumption, lesion site, and proliferation rates.
Material and Methods
Sample collection
The study protocol was approved by the Ethics Com-
mittee of Universidade Federal de Minas Gerais (ETIC 
48/08). Samples with clinical diagnosis of oral leuko-
plakias (OL) and normal oral epithelium (NOE) were 
gathered from the files of the Oral Pathology Service, 
Universidade Federal de Minas Gerais (UFMG), Brazil. 
Clinical records of each case were evaluated, and to-
bacco use was investigated. Sections of formalin-fixed, 
paraffin-embedded incisional biopsy specimens of the 
OL were evaluated by hematoxilin-eosin (HE) staining. 
Forty-eight OL were selected, separated according to 
site (high and low-risk) and classified histopathologi-
cally in two groups according to epithelial dysplasia 
(absence or presence) following the WHO recommen-
dation (3). The tongue and oral floor were considered 
high-risk sites, whereas all other intra-oral sites were 
considered low-risk (2,6). Cases located on the lip were 
not included in our study. Ten NOE, from different oral 
sites (low and high risk) were added for comparative 
purposes.
Immunohistochemistry (IHC)
IHC reactions for detection of EGFR, Ki-67, and p27 
antigens were performed using 31G7 monoclonal anti-
body clones (Zymed Laboratories Inc., San Francisco, 
CA, UK), MIB-1 (Dako, Carpinteria, USA), and SX5368 
(Dako, Carpinteria, USA), respectively. Briefly, 4µm sec-
tions were dewaxed in xylene and hydrated with graded 
ethanol. Blocking of endogenous peroxidase and avidin-
biotin activity was performed. Different protocols of an-
tigen retrieval were employed. The antigen retrieval for 
EGFR was performed with pepsin 10% at 37°C. For Ki-
67 and p27, the sections were placed in a steamer contai-
ning 10µm citric acid (pH 6.0) for 20 min and Tris/EDTA 
buffer (pH 8.0) for 20 min, respectively. The primary 
antibodies for EGFR and Ki-67 were incubated for 18 H 
at room temperature and diluted 1:100. The antibody for 
p27 was incubated for 18 H at 4°C and diluted 1:150. All 
dilutions were in 1% bovine serum albumin.
After rinsing in Tri-HCl buffer, sections were incubated 
for 30 minutes at room temperature with biotinylated 
multi-link swine anti-goat, mouse, and rabbit immu-
noglobulin (LSAB Kit, DaKo, Carpinteria, CA, USA). 
The reaction was revealed by applying diaminobenzi-
dine tetrahydrochloride (solid, DMBA). The sections 
were then counterstained with Mayer` s hematoxylin 
and mounted in Permount (Fisher Scientific, NJ, USA). 
Negative controls were obtained by the omission of the 
primary antibody.
Evaluation of IHC
The immunohistochemical stain was analyzed by a blind 
and calibrated examiner (RDC) EGFR expression was 
evaluated by the extent and intensity of EGFR immu-
nolabeling in cell membranes and classified on a four-
point scale as follows: 0 (no labeling or labeling <10% 
of epithelial cells), 1 (weak labeling, >10%), 2 (modera-
te labeling, >10%), and 3 (intense labeling, >10%). For 
data analysis, these categories were divided into two 
groups, 0 (negative; absent or weak labeling 0, 1) and 1 
(positive; moderate and intense 2, 3) (12,19).
Nuclear expression of Ki-67 and p27 was determined 
for each epithelial layer, including the basal layer (po-
sitive nuclei just above the basement membrane), the 
parabasal layer (positive nuclei within two layers above 
the basement membrane), and the suprabasal layer (po-
sitive nuclei in a more upper layer above the parabasal 
layer). The percentages of nuclei positively staining for 
Ki-67 and p27 in 500 epithelial cells for each layer were 
calculated as the labeling index (LI) (20).
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Based on Ki-67 and p27 expression levels in the oral 
epithelium (20-21), a cutoff value of 20% was set. This 
value was used to analyze the association between 
EGFR with Ki-67 and p27. To analyze the differences 
of cell proliferation in the presence and absence of dys-
plasia, the mean LIs for each layer were utilized.
Statistical procedures:
SPSS (Statistic Package for Social Sciences) 15.0 for 
Windows (SPSS Inc., Chicago, IL, USA) was used to 
analyze data. The differences in expression of EGFR 
were analyzed using the chi-square test and Fisher’s 
exact test (p < 0.05). T tests and Mann-Whitney tests (p 
< 0.05) were used to evaluate the differences of mean/
median LIs between dysplastic and non-dysplastic 
groups for Ki-67 and p27 in each layer. 
Results
Of the 48 cases analyzed, 28 were male and 20 were 
female. Ages ranged from 24 to 78 years of age, with 
a mean age of 53 years. With regards to anatomic loca-
tion, 34 were located in a low-risk site and 14 in a high-
risk site. Concerning tobacco consumption, 30 patients 
were smokers, and 18 were non-smokers. Twenty sam-
ples were histopathologically classified as hyperkerato-
sis with dysplasia, and 28 qualified as hyperkeratosis 
without dysplasia.
EGFR was positive in 30 (62.5%) cases of leukoplakia, 
and staining was localized to membranes and involved 
a basal extension to the suprabasal layers (Fig. 1). In 
NOE, EGFR was positive in 50% of the samples and the 
staining was restricted mainly to basal and parabasal 
layers. Although NOE of different sites were included, 
there was no association between the location of NOE 
and EGFR immunoexpression. 
In oral leukoplakia, EGFR immunoexpression did not 
show significant variation in the presence or absence of 
dysplasia or between smokers and non-smokers. There 
were differences in EGFR expression between leukopla-
kias in high and low-risk sites, with a higher number of 
EGFR positive lesions in high-risk than low-risk areas. 
When all epithelial layers were considered, p27 indexes 
were also significantly different between EGFR positi-
ve and negative leukoplakias. Most of the p27 negative 
leukoplakias were EGFR positive, but no significant di-
fference was seen for Ki-67 expression with respect to 
EGFR immunoexpression (Table 1).
Indexes for Ki-67 showed no significant difference bet-
ween dysplasia and non-dysplasia (Table 2). In contrast, 
indices for p27 were significantly lower in the parabasal 
layer of epithelium with dysplasia than the epithelium 
without dysplasia (Table 3).
Fig. 1. (A) Membranous staining for EGFR in oral leukoplakia (ar-
rowheads). Immunohistochemical staining, original magnification 
400x.
  EGFR p 
  Negative Positive Value 
Tobacco Non-smoker 4 14 0.090* 
 Smoker 14 16  
Risk area Low-risk area 16 18 0.033* 
 High-risk area 2 12  
Epithelial dysplasia Absence of dysplasia 11 17  
 Presence of dysplasia 7 13 0,762* 
LI Ki-67 (all layers) ≥20% 12 19 0.815* 
 <20% 6 11  
LI Ki-67 (basal layers) ≥20% 13 20 0.688* 
 <20% 5 13  
LI Ki-67 (parabasal layers) ≥20% 17 30 0.375° 
 <20% 1 0  
LI Ki-67 (suprabasal layers) ≥20% 1 1 1.000° 
 <20% 17 29  
LI p27 (all layers) ≥20% 13 12 0.031* 
 <20% 5 18  
LI p27 (basal layers) <20% 18 30 a 
LI p27 (parabasal layers) ≥20% 2 2 0.624° 
 <20% 16 28  
LI p27 (suprabasal layers) ≥20% 17 27 1.000° 
 <20% 1 3  
 
Table 1. Expression of EGFR according to tobacco smoking, loca-
tion of lesion, epithelial dysplasia, and cellular proliferation.
* Pearson chi-square °Fisher` s test,  a – no statistical analysis.
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Discussion
Previous studies have demonstrated increased EGFR 
expression in oral leukoplakias (13,15). In this study, we 
evaluated the influence of clinicopathological factors 
on the immunoexpression of EGFR in a group of oral 
leukoplakias as well as the association of EGFR and ce-
llular proliferation.
The methods for evaluation of EGFR immunoexpres-
sion are variable and include semiquantitative and au-
tomated analysis (12,15) with variable indexes and con-
sequently providing controversial results (13,22). Some 
studies employ methods of evaluation considering the 
extent and the intensity of the immunostaining, as used 
in this study (19) while other authors indicate strictly 
quantitative methods (23).
In leukoplakias it is generally accepted that histopatho-
logical characteristics of none or mild dysplasia have a 
lower risk of malignant transformation than moderate 
or severe dysplasia (2). Some reports describe a drama-
tic increase in EGFR expression with progression of a 
dysplastic lesion to cancer without significant differen-
ces among various grades of dysplasia (15,23). Consis-
tent with these prior findings, our results did not show 
differences in EGFR expression between dysplastic and 
non-dysplastic epithelium. 
In the present study, the tongue or floor of the mouth 
were considered to be high-risk sites for leukoplakia. 
This statement is consistent with prior studies (1,2). 
Differences were found in EGFR positivity between 
leukoplakias from high and low-risk sites. EGFR ex-
pression was more frequent in lesions from high-risk 
than low-risk areas. Another study (6) showed that leu-
koplakia at high-risk oral sites exhibited more advanced 
molecular changes (loss of heterozygosity - LOH) than 
were suggested by the histological findings. The present 
study reinforces the results of this molecular study. 
EGFR expression is associated with smoking history 
and is significantly upregulated in lung squamous cell 
carcinoma (24). Tobacco smoking is the strongest in-
dependent risk factor for leukoplakia, and studies show 
that there is a clear dose-dependent relationship for ci-
garettes (4-5) Interestingly; EGFR expression did not 
vary in leukoplakias from smokers and non-smokers. 
Because some reports have shown that tobacco smo-
king induces several EGFR ligands and subsequently 
leads to EGFR stimulation (25,26), we recommend that 
this topic should be further investigated.
Increased cellular proliferation in oral leukoplakia has 
been reported in prior studies (20-21, 27-28) and was 
confirmed by the present results. Although the Ki-67 
LIs value did not correlate with corresponding EGFR 
positivity or with the presence of dysplasia, the present 
study confirmed an extended suprabasal expression of 
Ki-67 in leukoplakia (20). Likewise, although no diffe-
rence in the Ki-67 LIs associated with dysplasia was 
found, this index tended to be more pronounced in dys-
plastic epithelium.
The CDK inhibitor p27 plays an important role in G2 
arrest by binding to and inhibiting G1 cyclin (a CDK 
complex) and negatively regulating progression through 
the G1 and S phases of the cell cycle. Reduced levels of 
p27 have been reported in a number of human tumors 
and have been associated with aggressive histological 
behavior (29). In the present study, 23 (48%) of the leu-
koplakias were negative for p27.
A reduction in the expression of p27 in oral leukopla-
 KiBPerc° KiPbPerc* KiSbPerc° KiTPerc° 
 Median Mean Median Median 
Absence of dysplasia 21,21 42,3639 24,91 23,18 
Presence of dysplasia 29,10 37,6595 23,92 26,35 
p Value 0,054 0,065 0,810 0,439 
 
Table 2. Mean values of Ki-67 labeling indices (LI) in epithelial layers of leuko-
plakias.
*T test ° Mann-Whitney test.
 p27BPerc ° p27PbPerc° p27SbPerc* p27TPerc* 
 Median Median Mean Mean 
Abscence of dysplasia 26,50 28,82 50,9775 22,4464 
Presence of dysplasia 21,70 18,45 39,0120 15,8020 
p Value 0,242 0,011 0,834 0,521 
 
Table 3. Mean values of p27 labeling indices (LI) in epithelial layers of leukoplakias.
*T test  °Mann-Whitney test p value ≤0.05.
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kia in comparison with normal oral epithelium has been 
described in previous studies (21,  29-30) but the role of 
EGFR in this reduction has not been explored yet. The le-
vels of p27 are mainly regulated via post-transcriptional 
mechanisms, including ubiquitin-proteosome-mediated 
proteolysis. The majority of p27 in tumor cells is regula-
ted by ubiquitin degradation (18), and an upregulation of 
p27 has been associated with downregulation of skp2 via 
erbB-2 or EGFR inhibition (16,18,31). 
In the present sample there was a significant difference 
between p27 positive and negative leukoplakias. Most of 
the p27 negative leukoplakias were EGFR positive. Pre-
vious studies have shown that gefitinib (ZD1839, Iressa), 
an EGFR tyrosine kinase inhibitor, causes growth arrest 
“in vitro” coincident with upregulation of p27 (16-18) 
Our results are consistent with these findings and suggest 
that EGFR exerts a role in the control of cell proliferation 
in OL via p27, but not enhancing Ki-67.
An association between p27 and dysplasia was also ob-
served in the parabasal layer of epithelium. Expression 
of p27 tended to be reduced in presence of dysplasia, 
which is in accordance with previous findings (21,30). 
This suggests that alterations in p27 expression may 
precede the invasive stages of oral tumorigenesis and 
reflect changes in growth control of dysplastic cells. 
In conclusion EGFR expression is frequent in oral leu-
koplakia, especially in those lesions located on floor of 
the mouth and on the tongue. The association of p27 
with EGFR warrants additional investigation, and, in 
the future, may allow for new treatment options for se-
vere leukoplakias through EGFR inhibitors.
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